Nichols & Pratt Advisers LLP MA Has $39.71 Million Holdings in Novartis AG (NVS)

Nichols & Pratt Advisers LLP MA lowered its position in shares of Novartis AG (NYSE:NVS) by 0.2% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 413,114 shares of the company’s stock after selling 800 shares during the quarter. Novartis comprises approximately 3.3% of Nichols & Pratt Advisers LLP MA’s portfolio, making the stock its 8th biggest position. Nichols & Pratt Advisers LLP MA’s holdings in Novartis were worth $39,705,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the company. BlackRock Inc. increased its holdings in Novartis by 223.5% in the 4th quarter. BlackRock Inc. now owns 11,439,298 shares of the company’s stock worth $981,607,000 after buying an additional 7,902,964 shares in the last quarter. FMR LLC increased its holdings in Novartis by 441.6% in the 4th quarter. FMR LLC now owns 7,016,047 shares of the company’s stock worth $602,046,000 after buying an additional 5,720,650 shares in the last quarter. Bank of America Corp DE increased its holdings in Novartis by 25.1% in the 4th quarter. Bank of America Corp DE now owns 9,053,828 shares of the company’s stock worth $776,909,000 after buying an additional 1,817,005 shares in the last quarter. Mawer Investment Management Ltd. increased its holdings in Novartis by 53.4% in the 4th quarter. Mawer Investment Management Ltd. now owns 4,764,486 shares of the company’s stock worth $408,841,000 after buying an additional 1,658,037 shares in the last quarter. Finally, Boston Partners increased its holdings in Novartis by 26.1% in the 4th quarter. Boston Partners now owns 7,046,794 shares of the company’s stock worth $604,685,000 after buying an additional 1,459,845 shares in the last quarter. Hedge funds and other institutional investors own 11.82% of the company’s stock.

Shares of NVS stock traded up $3.08 during trading hours on Friday, reaching $87.52. 4,711,326 shares of the company traded hands, compared to its average volume of 2,540,707. The company has a quick ratio of 0.83, a current ratio of 0.93 and a debt-to-equity ratio of 0.48. Novartis AG has a 12-month low of $63.60 and a 12-month high of $85.08. The stock has a market cap of $195.06 billion, a P/E ratio of 17.19, a PEG ratio of 1.98 and a beta of 0.66.

Novartis (NYSE:NVS) last posted its quarterly earnings results on Wednesday, April 24th. The company reported $1.21 EPS for the quarter, topping the Zacks’ consensus estimate of $1.11 by $0.10. Novartis had a return on equity of 16.75% and a net margin of 24.55%. The company had revenue of $11.11 billion for the quarter, compared to analysts’ expectations of $11.76 billion. During the same period in the previous year, the firm earned $1.28 EPS. The firm’s revenue was up 1.7% compared to the same quarter last year. On average, equities research analysts expect that Novartis AG will post 5 earnings per share for the current fiscal year.

Several research firms recently commented on NVS. Liberum Capital upgraded Novartis from a “hold” rating to a “buy” rating in a report on Thursday, April 25th. Zacks Investment Research downgraded Novartis from a “hold” rating to a “strong sell” rating in a research note on Thursday, April 11th. Guggenheim upgraded Novartis from a “neutral” rating to a “buy” rating and set a $79.16 price target for the company in a research note on Wednesday, April 24th. Morgan Stanley downgraded Novartis from an “equal weight” rating to an “underweight” rating and boosted their price target for the company from $82.50 to $82.52 in a research note on Wednesday, April 10th. Finally, JPMorgan Chase & Co. restated a “sell” rating on shares of Novartis in a research note on Tuesday, January 29th. Five equities research analysts have rated the stock with a sell rating, four have given a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $87.57.

TRADEMARK VIOLATION NOTICE: “Nichols & Pratt Advisers LLP MA Has $39.71 Million Holdings in Novartis AG (NVS)” was first reported by Sundance Herald and is the sole property of of Sundance Herald. If you are viewing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark law. The legal version of this piece of content can be viewed at https://sundanceherald.com/2019/05/24/novartis-ag-nvs-shares-sold-by-nichols-pratt-advisers-llp-ma.html.

About Novartis

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, cardio-metabolic, and established medicine products.

See Also: Return On Assets

Institutional Ownership by Quarter for Novartis (NYSE:NVS)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply